ET
SMMT icon

Entropy Technologies’s Summit Therapeutics SMMT Stock Holding History

Entropy Technologies’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$831K Buy
57,017
+35,234
+162% +$625K 0.03% 553
2026
Q1 		$413K Sell
21,783
-3,379
-13% -$54.6K 0.02% 628
2025
Q4 		$440K Buy
+25,162
New +$473K 0.02% 593

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Entropy Technologies's SMMT Position: Q2 2026 in Review

Entropy Technologies increased its Summit Therapeutics (SMMT) stake by 162% in Q2 2026, buying an estimated $625K and bringing the position to 57,017 shares worth $831K. The position accounts for 0.03% of the portfolio, ranked #553.

Entropy Technologies first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Entropy Technologies held 57,017 shares of Summit Therapeutics worth $831K as of Q2 2026.
  • Entropy Technologies bought 35,234 Summit Therapeutics shares in Q2 2026, an estimated $625K.
  • Summit Therapeutics made up 0.03% of Entropy Technologies's portfolio in Q2 2026, its #553 holding.
  • Entropy Technologies first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.